Literature DB >> 17449181

Analgesic properties of oleoylethanolamide (OEA) in visceral and inflammatory pain.

Margarita Suardíaz1, Guillermo Estivill-Torrús, Carlos Goicoechea, Ainhoa Bilbao, Fernando Rodríguez de Fonseca.   

Abstract

Oleoylethanolamide (OEA) is a natural fatty acid amide that mainly modulates feeding and energy homeostasis by binding to peroxisome proliferator-activated receptor-alpha (PPAR-alpha) [Rodríguez de Fonseca F, Navarro M, Gómez R, Escuredo L, Navas F, Fu J, et al. An anorexic lipid mediator regulated by feeding. Nature 2001;414:209-12; Fu J, Gaetani S, Oveisi F, Lo Verme J, Serrano A, Rodríguez de Fonseca F, et al. Oleoylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. Nature 2003;425:90-3]. Additionally, it has been proposed that OEA could act via other receptors, including the vanilloid receptor (TRPV1) [Wang X, Miyares RL, Ahern GP. Oleoylethanolamide excites vagal sensory neurones, induces visceral pain and reduces short-term food intake in mice via capsaicin receptor TRPV1. J Physiol 2005;564:541-7.] or the GPR119 receptor [Overton HA, Babbs AJ, Doel SM, Fyfe MC, Gardner LS, Griffin G, et al. Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents. Cell Metab 2006;3:167-175], suggesting that OEA might subserve other physiological roles, including pain perception. We have evaluated the effect of OEA in two types of nociceptive responses evoked by visceral and inflammatory pain in rodents. Our results suggest that OEA has analgesic properties reducing the nociceptive responses produced by administration of acetic acid and formalin in two experimental animal models. Additional research was performed to investigate the mechanisms underlying this analgesic effect. To this end, we evaluated the actions of OEA in mice null for the PPAR-alpha receptor gene and compared its actions with those of PPAR-alpha receptor wild-type animal. We also compared the effect of MK-801 in order to evaluate the role of NMDA receptor in this analgesia. Our data showed that OEA reduced visceral and inflammatory responses through a PPAR-alpha-activation independent mechanism. Co-administration of subanalgesic doses of MK-801 and OEA produced an analgesic effect, suggesting the participation of glutamatergic transmission in the antinociceptive effect of OEA. This study represents a novel approach to the examination of the effectiveness of OEA in nociceptive responses and provides a framework for understanding its biological functions and endogenous targets in visceral and inflammatory pain.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17449181     DOI: 10.1016/j.pain.2007.03.008

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  53 in total

1.  PPARα agonists--an emerging concept in the management of neuropathic and visceral pain.

Authors:  Shailendra Kapoor
Journal:  Psychopharmacology (Berl)       Date:  2012-03-30       Impact factor: 4.530

2.  Anti-obesity efficacy of LH-21, a cannabinoid CB(1) receptor antagonist with poor brain penetration, in diet-induced obese rats.

Authors:  Mónica Alonso; Antonia Serrano; Margarita Vida; Ana Crespillo; Laura Hernandez-Folgado; Nadine Jagerovic; Pilar Goya; Carmen Reyes-Cabello; Vidal Perez-Valero; Juan Decara; Manuel Macías-González; Francisco Javier Bermúdez-Silva; Juan Suárez; Fernando Rodríguez de Fonseca; Francisco Javier Pavón
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

Review 3.  International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂.

Authors:  R G Pertwee; A C Howlett; M E Abood; S P H Alexander; V Di Marzo; M R Elphick; P J Greasley; H S Hansen; G Kunos; K Mackie; R Mechoulam; R A Ross
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

4.  Cannabinoid type-1 receptor reduces pain and neurotoxicity produced by chemotherapy.

Authors:  Iryna A Khasabova; Sergey Khasabov; Justin Paz; Catherine Harding-Rose; Donald A Simone; Virginia S Seybold
Journal:  J Neurosci       Date:  2012-05-16       Impact factor: 6.167

5.  Evaluation of fatty acid amides in the carrageenan-induced paw edema model.

Authors:  Laura E Wise; Roberta Cannavacciulo; Benjamin F Cravatt; Billy F Martin; Aron H Lichtman
Journal:  Neuropharmacology       Date:  2007-06-22       Impact factor: 5.250

6.  Effects of the noncompetitive N-methyl-d-aspartate receptor antagonists ketamine and MK-801 on pain-stimulated and pain-depressed behaviour in rats.

Authors:  T M Hillhouse; S S Negus
Journal:  Eur J Pain       Date:  2016-02-23       Impact factor: 3.931

Review 7.  Cannabinoids in chronic non-cancer pain medicine: moving from the bench to the bedside.

Authors:  H Meng; A Deshpande
Journal:  BJA Educ       Date:  2020-07-21

8.  Role of the satiety factor oleoylethanolamide in alcoholism.

Authors:  Ainhoa Bilbao; Antonia Serrano; Andrea Cippitelli; Francisco J Pavón; Andrea Giuffrida; Juan Suárez; Nuria García-Marchena; Elena Baixeras; Raquel Gómez de Heras; Laura Orio; Francisco Alén; Roberto Ciccocioppo; Benjamin F Cravatt; Loren H Parsons; Daniele Piomelli; Fernando Rodríguez de Fonseca
Journal:  Addict Biol       Date:  2015-06-02       Impact factor: 4.280

Review 9.  Cannabinoids in the descending pain modulatory circuit: Role in inflammation.

Authors:  Courtney A Bouchet; Susan L Ingram
Journal:  Pharmacol Ther       Date:  2020-01-29       Impact factor: 12.310

10.  N-oleoyldopamine enhances glucose homeostasis through the activation of GPR119.

Authors:  Zhi-Liang Chu; Chris Carroll; Ruoping Chen; Jean Alfonso; Veronica Gutierrez; Hongmei He; Annette Lucman; Charles Xing; Kristen Sebring; Jinyao Zhou; Brandee Wagner; David Unett; Robert M Jones; Dominic P Behan; James Leonard
Journal:  Mol Endocrinol       Date:  2009-11-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.